Rheumatology
Journal Abbreviation: RHEUMATOLOGY
ISSN: 1462-0324
eISSN: 1462-0332
Publisher: Oxford University Press
Publications (87)
Comment on: Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome: reply (2020)
Ozguler Y, Hatemi G, Cetinkaya F, Tascilar K, Hamuryudan V, Ugurlu S, Seyahi E, et al.
Journal article, Note
Enthesitis in psoriatic arthritis (Part 1): pathophysiology (2020)
Araujo EG, Schett G
Journal article
Calcium pyrophosphate deposition disease induced inflammatory back pain (2020)
Kleyer A, Knitza J, Schett G, Manger B
Journal article
Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. (2020)
Mihai C, Distler O, Gheorghiu AM, Constantin P, Dobrota R, Jordan S, Smith V, et al.
Journal article
Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response (2019)
Toussaint F, Hammon M, Erdmann M, Moreira A, Kirchberger MC, Schuler G, Schett G, Heinzerling L
Journal article
Analyses of association of psoriatic arthritis and psoriasis vulgaris with functional NCF1 variants (2019)
Löhr S, Ekici AB, Uebe S, Büttner C, Köhm M, Behrens F, Böhm B, et al.
Journal article
EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN THE GIACTA TRIAL (2019)
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, et al.
Conference contribution
Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial (2019)
Tahir H, Mease PJ, Kavanaugh A, Reimold A, Rech J, Hall S, Geusens P, et al.
Conference contribution
GENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE (2019)
Wong L, Mescia F, Alberici F, Ball MJ, Baslund B, Brenchley P, Bruchfeld A, et al.
Conference contribution
EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL (2019)
Stone J, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, et al.
Conference contribution